Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

161. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting Full Text available with Trip Pro

Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting To determine if clopidogrel use before coronary artery bypass grafting (CABG) is associated with an increase in major bleeding, hemorrhage-related complications, or transfusion requirements.A structured literature search of English-language articles was conducted by using MEDLINE, EMBASE, and the Cochrane Collaboration Database for the period of January 1, 1990-April 30, 2007 (...) . Studies were included if they met the following criteria: randomized controlled trials, prospective observational trials, or retrospective trials; characteristics and outcomes of patients who were exposed to clopidogrel within 7 days before CABG were analyzed; at least 20 patients were enrolled; and reported outcomes were related to transfusion requirements, resource utilization, clinical events, or hemorrhage-related reoperation rates. Patients were considered exposed to clopidogrel

2008 EvidenceUpdates

162. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel Full Text available with Trip Pro

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year.We performed 1-year (...) follow-up of 2022 high-risk patients with NSTE-ACS undergoing urgent PCI, who were randomized to abciximab or placebo after pre-treatment with 600 mg clopidogrel in the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. The combined incidence of death, myocardial infarction, or target vessel revascularization at 1 year was the primary outcome analysis. At 1 year, the primary outcome was reached in 23.3% of patients allocated to abciximab vs. 28.0

2008 EvidenceUpdates Controlled trial quality: predicted high

163. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. Full Text available with Trip Pro

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. It is unknown whether patients are at increased short-term risk for adverse events following clopidogrel cessation.To assess the rates of adverse events after stopping treatment with clopidogrel in a national sample of patients with acute coronary syndrome (ACS).Retrospective cohort study of 3137 patients with ACS discharged from 127 Veterans Affairs hospitals between October 1 (...) , 2003, and March 31, 2005, with posthospital treatment with clopidogrel.Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel.Mean (SD) follow-up after stopping treatment with clopidogrel was 196 (152) days for medically treated patients with ACS without stents (n = 1568) and 203 (148) days for patients with ACS treated with percutaneous coronary intervention (PCI) (n = 1569). Among medically treated patients, mean (SD) duration of clopidogrel

2008 JAMA

164. Clopidogrel Zentiva (previously Clopidogrel Winthrop) - clopidogrel

Clopidogrel Zentiva (previously Clopidogrel Winthrop) - clopidogrel European Medicines Agency Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea.europa.eu http://www.emea.europa.eu © European Medicines Agency, 2008. Reproduction is authorised provided the source is acknowledged Doc.Ref.: EMEA/253029/2008 ASSESSMENT REPORT FOR Clopidogrel Winthrop International Nonproprietary Name (...) : clopidogrel Procedure No. EMEA/H/C/000975 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 2/5 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission of the dossier 3 1.2 Steps taken for the assessment of the product 3 2 SCIENTIFIC DISCUSSION 4 2.1 Introduction 4 2.2 Quality aspects 4 2.3 Non-clinical aspects 4 2.4 Clinical aspects 5 2.5 Pharmacovigilance 5 2.6 Overall conclusions, risk/benefit assessment and recommendation

2008 European Medicines Agency - EPARs

165. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. Full Text available with Trip Pro

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel.In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel (...) daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned.A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval

2008 NEJM Controlled trial quality: predicted high

166. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. Full Text available with Trip Pro

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. The arteriovenous fistula is the preferred type of vascular access for hemodialysis because of lower thrombosis and infection rates and lower health care expenditures compared with synthetic grafts or central venous catheters. Early failure of fistulas due to thrombosis or inadequate maturation is a barrier to increasing the prevalence of fistulas among patients treated (...) with hemodialysis. Small, inconclusive trials have suggested that antiplatelet agents may reduce thrombosis of new fistulas.To determine whether clopidogrel reduces early failure of hemodialysis fistulas.Randomized, double-blind, placebo-controlled trial conducted at 9 US centers composed of academic and community nephrology practices in 2003-2007. Eight hundred seventy-seven participants with end-stage renal disease or advanced chronic kidney disease were followed up until 150 to 180 days after fistula

2008 JAMA Controlled trial quality: predicted high

167. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany Full Text available with Trip Pro

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany Berger K, Hessel F, Kreuzer J, Smala A, Diener H C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of clopidogrel versus aspirin as secondary prevention for patients who had experienced myocardial infarction or ischaemic stroke or were diagnosed with peripheral arterial disease. The authors concluded that clopidogrel was a cost

2008 NHS Economic Evaluation Database.

168. Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials

Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

169. Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials

Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

170. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting

Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting Pickard A S, Becker R C, Schumock G T, Frye C B CRD summary The authors concluded that exposure to clopidogrel in the seven days before coronary artery bypass (...) grafting was associated with an increase in bleeding-related complications. Due to reliance on potentially biased retrospective studies and because of differences between studies, the authors’ conclusions may not be reliable. Authors' objectives To determine if clopidogrel given prior to coronary artery bypass grafting (CABG) increased bleeding-related events. Searching MEDLINE, EMBASE (both 1990 to April 2007) and the Cochrane Database of Systematic Reviews were searched for studies published

2008 DARE.

171. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events Full Text available with Trip Pro

Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events Bowry A D, Brookhart M A, Choudhry N K CRD summary (...) The authors concluded that combined clopidogrel and aspirin reduced the likelihood of major cardiovascular events associated with acute coronary syndrome or percutaneous coronary intervention compared with monotherapy, but increased the likelihood of major bleeding. Although the review had limitations, in particular the restriction to published studies in English, in most respects it was well conducted and the conclusions appeared reliable. Authors' objectives To evaluate the role of dual antiplatelet

2008 DARE.

172. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) Full Text available with Trip Pro

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk

2008 EvidenceUpdates Controlled trial quality: uncertain

173. Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery?

Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? BestBets: Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Does clopidogrel rather than aspirin plus a proton-pump inhibitor reduce the frequency of gastrointestinal complications after cardiac surgery? Report By: Maren Ziegelin, Andreas Hoschtitzky, Joel (...) Dunning, and Tim Hooper - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Specialist Registrar in Cardiothoracic Surgery RCS Institution: Department of Cardiothoracic Surgery, Wythenshawe Hospital, Manchester and ames Cook University Hospital, Middlesbrough Date Submitted: 24th July 2007 Date Completed: 17th October 2007 Last Modified: 17th October 2007 Status: Green (complete) Three Part Question In patients undergoing [cardiac surgery] is [clopidogrel superior

2007 BestBETS

174. Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury

Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury BestBets: Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury Does Clopidogrel Increase Morbidity and Mortality After Minor Head Injury Report By: Dr Richard Parris - Consultant in Emergency Medicine Search checked by Dr Zia Hassan - Registrar in Emergency Medicine, Hope Hospital Institution: Royal Bolton Hospital Date Submitted: 17th February 2006 Date Completed: 29th May 2007 Last Modified: 12th (...) April 2007 Status: Green (complete) Three Part Question In a patient with a [head injury], does concurrent [treatment with clopidogrel] [increase morbidity and mortality]? Clinical Scenario A 78-year old male presents to the Emergency Department in a coma two days after a minor head injury. You note he is taking clopidogrel for treatment of his ischaemic heart disease. CT scan shows a large sub-dural haematoma. You wonder whether the clopidogrel has contributed to the development of this haematoma

2007 BestBETS

175. Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Full Text available with Trip Pro

Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Article Text

2007 Evidence-Based Medicine

176. Role of clopidogrel in managing atherothrombotic cardiovascular disease. (Abstract)

Role of clopidogrel in managing atherothrombotic cardiovascular disease. Aspirin is the most widely used antiplatelet agent for preventing and treating vascular events. The thienopyridine derivatives, ticlopidine and clopidogrel, are a suitable alternative in patients who are intolerant to aspirin, and clopidogrel exhibits better tolerability than ticlopidine. The available evidence from randomized trials indicates that dual therapy with clopidogrel and aspirin is modestly but significantly (...) of platelet glycoprotein IIb/IIIa inhibitors, and the exact mechanism and clinical relevance of clopidogrel resistance are unclear.

2007 Annals of Internal Medicine

177. Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting?

Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? BestBets: Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? Should high risk patients receive clopidogrel as well as aspirin post coronary arterial bypass grafting? Report By: Babu Kunadian, Andrew R. Thornley, Thotala N. Babu - Specialist Registrars in Cardiothoracic Surgery Search checked by Joel Dunning - Cardiothoracic Registrar RCS (...) Institution: Department of Cardiothoracic Surgery, James Cook University Hospital and Department of Cardiology, Lincoln Medical Health Center, New York Date Submitted: 21st December 2006 Date Completed: 13th February 2007 Last Modified: 13th March 2007 Status: Green (complete) Three Part Question In patients post [urgent coronary arterial bypass grafting] should [clopidogrel be given in addition to aspirin] to reduce the chance of [thrombotic complications]. Clinical Scenario You are reviewing a 55-year

2007 BestBETS

178. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Full Text available with Trip Pro

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis.To assess the association between clopidogrel use and long-term clinical outcomes of patients receiving drug-eluting stents (DES) and bare-metal stents (BMS) for treatment of coronary artery disease.An observational study examining consecutive patients receiving (...) . At these points, patients were divided into 4 groups based on stent type and self-reported clopidogrel use: DES with clopidogrel, DES without clopidogrel, BMS with clopidogrel, and BMS without clopidogrel.Death, nonfatal MI, and the composite of death or MI at 24-month follow-up.Among patients with DES who were event-free at 6 months (637 with and 579 without clopidogrel), clopidogrel use was a significant predictor of lower adjusted rates of death (2.0% with vs 5.3% without; difference, -3.3%; 95% CI, -6.3

2007 JAMA

179. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials Helton T J, Bavry A A, Kumbhani D J, Duggal S, Roukoz H, Bhatt D L CRD summary The authors (...) concluded that the addition of clopidogrel to aspirin slightly reduces all-cause and cardiovascular mortality in patients with ST-elevation myocardial infarction (STEMI), and modestly reduces myocardial infarction and stroke in patients with cardiovascular disease, but also increases bleeding. The review was generally well-conducted, but the lack of results data undermines the conclusion about the subgroup of STEMI patients. The other conclusions appear reliable. Authors' objectives To compare

2007 DARE.

180. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention

Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.